Windlas Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Windlas Biotech Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 13% of its market value (net cash). Higher than 93% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹152Over the last 3 years, every ₹100 of reported profit came with ₹152 of operating cash.
Higher than 70% of Healthcare companies in India.
Self-Funding Ratio
1.8×Over the last 3 years its own operating cash covered its investment spending (capex) 1.8 times.
Higher than 64% of Healthcare companies in India.
Cash Locked Ratio
₹2For every ₹100 of sales, ₹2 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹18 tied up three years earlier.
Less money tied up than 84% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹6Sales grew 76% in 3 years; of every extra ₹100 of sales, ₹6 became extra profit.
Lower than 77% of Healthcare companies in India.
Asset Productivity Ratio
+76% / +72%In 3 years sales changed by +76% while total assets changed by +72%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
3.5×Debt due within a year is covered 3.5 times by its yearly operating cash.
Higher than 68% of Healthcare companies in India.
Cash Cushion Ratio
+13%Cash, after subtracting all debt, equals 13% of its market value (net cash).
Higher than 93% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 64% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 65% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Windlas Biotech Limited owes ₹0.36 for every ₹1 it owns. Net profit rose 9% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
27.9Investors pay ₹27.9 for every ₹1 of Windlas Biotech Limited's yearly profit, lower than 67% of Healthcare companies in India.
P/B ratio
3.10The share price is 3.10 times Windlas Biotech Limited's book value per share, lower than 69% of Healthcare companies in India.
Market cap
₹1,801 CrThe total market value of all of Windlas Biotech Limited's shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹581 CrWhat Windlas Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹281.47Net worth divided by the number of shares. The share price of ₹872.70 is 3.1 times this, which is the P/B above.
Return on equity (ROE)
11.4%Windlas Biotech Limited earned 11.4% on its shareholders' money over the last year, lower than 58% of Healthcare companies in India.
Owes vs Owns
0.36×Windlas Biotech Limited owes ₹0.36 for every ₹1 it owns (low), lower than 54% of Healthcare companies in India.
Dividend yield
0.67%Windlas Biotech Limited pays 0.67% of its share price as dividends a year, higher than 73% of dividend-paying Healthcare companies in India.
Revenue growth
+19%Revenue rose 19% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Profit growth
+9%Net profit rose 9% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Profit margin
7.4%Windlas Biotech Limited keeps ₹7 of every ₹100 of revenue as net profit.
Cash quality
1.6×Cash from Windlas Biotech Limited's business was 1.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
15.4×Windlas Biotech Limited's operating profit covered its interest costs 15.4 times in the year to Mar 2026.
Cash vs debt
Net cashWindlas Biotech Limited held ₹244 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Windlas Biotech Limited's P/E ratio?
Investors pay ₹27.9 for every ₹1 of Windlas Biotech Limited's yearly profit, lower than 67% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Windlas Biotech Limited: ₹1,801 Cr ÷ ₹581 Cr (31 Mar 2026) = 3.1.
What is Windlas Biotech Limited's return on equity?
Windlas Biotech Limited earned 11.4% on its shareholders' money over the last year, lower than 58% of Healthcare companies in India.
How much does Windlas Biotech Limited owe compared with what it owns?
Windlas Biotech Limited owes ₹0.36 for every ₹1 it owns (low), lower than 54% of Healthcare companies in India.
Does Windlas Biotech Limited pay a dividend?
Yes. Windlas Biotech Limited pays 0.67% of its share price as dividends a year, higher than 73% of dividend-paying Healthcare companies in India.
Is Windlas Biotech Limited's revenue growing?
Revenue rose 19% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.